By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax Corp.  Antibody phage display





Company News
Biogen (BIIB) Reports First Quarter 2015 Revenues Of $2.6 Billion 4/24/2015 7:45:51 AM
Can Biogen (BIIB) Really Beat Alzheimer's? 4/24/2015 7:21:58 AM
Biogen (BIIB) Loaded With Talented Women Execs, as CEO Pushes to Diversify Boardroom 4/22/2015 8:20:57 AM
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015 6:30:33 AM
Biogen (BIIB) Release: PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented At American Academy of Neurology Annual Meeting Support Long-Term Safety And Efficacy In Multiple Sclerosis Patients 4/21/2015 11:32:59 AM
International Survey From Biogen (BIIB) Identifies Opportunities For Improving MS Treatment Satisfaction 4/21/2015 11:28:54 AM
Biogen (BIIB) Release: TECFIDERA (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy For Newly-Diagnosed MS Patients 4/20/2015 1:23:19 PM
Biogen (BIIB) Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4/16/2015 12:05:41 PM
U.S. Patent Office Declares An Interference Between Forward Pharma (FWP) And Biogen (BIIB) Regarding The Treatment Of Multiple Sclerosis With 480 Mg Daily Dose Of DMF, The Active Ingredient In Tecfidera 4/15/2015 3:36:20 PM
Biogen (BIIB) Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair 4/15/2015 11:17:40 AM
12345678910...
//-->